Gross Profit Comparison: GSK plc and Teva Pharmaceutical Industries Limited Trends

GSK vs. Teva: A Decade of Diverging Profits

__timestampGSK plcTeva Pharmaceutical Industries Limited
Wednesday, January 1, 20141568300000011056000000
Thursday, January 1, 20151507000000011356000000
Friday, January 1, 20161859900000011859000000
Sunday, January 1, 20171984400000010825000000
Monday, January 1, 2018205800000008296000000
Tuesday, January 1, 2019218910000007536000000
Wednesday, January 1, 2020223950000007725000000
Friday, January 1, 2021225110000007594000000
Saturday, January 1, 2022197700000006973000000
Sunday, January 1, 2023217630000007646000000
Monday, January 1, 20248064000000
Loading chart...

Unlocking the unknown

A Decade of Gross Profit Trends: GSK plc vs. Teva Pharmaceutical Industries Limited

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. Over the past decade, GSK plc and Teva Pharmaceutical Industries Limited have showcased contrasting trajectories in their gross profits. From 2014 to 2023, GSK plc has consistently outperformed Teva, with its gross profit peaking at approximately 22.5 billion in 2021, marking a 43% increase from 2014. In contrast, Teva's gross profit has seen a decline, dropping by 37% from its 2016 peak of around 11.9 billion to 7.6 billion in 2023. This divergence highlights GSK's robust growth strategy and market adaptability, while Teva faces challenges in maintaining its financial momentum. As the pharmaceutical landscape continues to shift, these trends offer valuable insights into the strategic directions of these industry giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025